Carlos Gómez-Martín
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carlos Gómez-Martín has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Ana Fernández Montes
Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain
5 shared publications - Fernando Rivera
Medical Oncology Department, Hospital Universitario Marqués de Valdecilla and Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
5 shared publications - Maria Alsina
Medical Oncology Department, Hospital Universitario de Navarra (HUN), Navarrabiomed - Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
5 shared publications - Ana Custodio
Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain
3 shared publications - Fredrik Öberg
10Medivir AB, Huddinge, Sweden
3 shared publications - Hans Wallberg
10Medivir AB, Huddinge, Sweden
3 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in Clinical and Translational Oncology
- p. 1-3
Correction: SEOM–GEMCAD–TTD clinical guideline for the diagnosis and treatment of esophageal cancer (update 2025)
- 15 October 2026
- Published by Springer Nature in Clinical and Translational Oncology
- p. 1-3
Open AccessCorrection: SEOM–GEMCAD–TTD clinical guideline for the diagnosis and treatment of esophageal cancer (update 2025)
- Open Access
Intensive Care in Patients with Solid Tumours: A Practical Framework for Integrated Onco-Critical Care
The number of patients with solid tumours requiring intensive care is increasing as cancer survival improves and oncological treatments become more complex. Intensive care unit (ICU) admission decisions should not be based on cancer diagnosis, metastatic status or palliative treatment intent alone. This narrative review presents a practical, multidisciplinary framework for assessing critically ill patients with solid tumours. It integrates acute illness severity and reversibility, organ failure, baseline performance status and frailty, cancer trajectory, remaining treatment options, expected functional recovery and patient preferences. We discuss contemporary anticancer treatment toxicities, cancer-associated thromboembolic disease, older adults, palliative care, communication and ethical decision-making. We also propose an algorithm ranging from full ICU support to a time-limited ICU trial with predefined reassessment or comfort-focused care. Early joint assessment by oncology and intensive care teams, followed by dynamic reassessment, may reduce both inappropriate escalation and premature exclusion from potentially beneficial organ support. Future research should prioritize structured pathways, improved prognostic tools and outcomes beyond survival, including functional recovery, quality of life and the ability to resume meaningful cancer treatment.
Open AccessIntensive Care in Patients with Solid Tumours: A Practical Framework for Integrated Onco-Critical Care
The number of patients with solid tumours requiring intensive care is increasing as cancer survival improves and oncological treatments become more complex. Intensive care unit (ICU) admission decisions should not be based on cancer diagnosis, metastatic status or palliative treatment intent alone. This narrative review presents a practical, multidisciplinary framework for assessing critically ill patients with solid tumours. It integrates acute illness severity and reversibility, organ failure, baseline performance status and frailty, cancer trajectory, remaining treatment options, expected functional recovery and patient preferences. We discuss contemporary anticancer treatment toxicities, cancer-associated thromboembolic disease, older adults, palliative care, communication and ethical decision-making. We also propose an algorithm ranging from full ICU support to a time-limited ICU trial with predefined reassessment or comfort-focused care. Early joint assessment by oncology and intensive care teams, followed by dynamic reassessment, may reduce both inappropriate escalation and premature exclusion from potentially beneficial organ support. Future research should prioritize structured pathways, improved prognostic tools and outcomes beyond survival, including functional recovery, quality of life and the ability to resume meaningful cancer treatment.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data1 from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
Contents: Figure S1. Longitudinal measure of ALT, AST,total bilirubin levels, and ALBI score. Figure S2. Longitudinal measure of neutrophil levels and thrombocyte levels Figure S3. Dose reduction and discontinuation due to adverse events Figure S4. Pharmacokinetics; plasma concentrations for fostrox and troxacitabine Figure S5. Liver biopsy PD marker expression Table S1. Exposure to fostrox and troxacitabine in plasma after one cycle of fostrox administration Table S2. Representativeness of Study Participants
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data1 from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
Contents: Figure S1. Longitudinal measure of ALT, AST,total bilirubin levels, and ALBI score. Figure S2. Longitudinal measure of neutrophil levels and thrombocyte levels Figure S3. Dose reduction and discontinuation due to adverse events Figure S4. Pharmacokinetics; plasma concentrations for fostrox and troxacitabine Figure S5. Liver biopsy PD marker expression Table S1. Exposure to fostrox and troxacitabine in plasma after one cycle of fostrox administration Table S2. Representativeness of Study Participants
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Data from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
Purpose:Immunotherapy has significantly improved outcomes in advanced hepatocellular carcinoma (HCC). However, most patients eventually progress, and second-line (2L) options remain limited. Fostroxacitabine bralpamide (fostrox), a liver-targeted prodrug, was administered in combination with lenvatinib, aiming at enhancing antitumor activity while avoiding further deterioration of residual liver function. Patients and Methods:This multicenter, single-arm phase Ib/IIa study evaluated the safety, pharmacokinetics (PK)/pharmacodynamics, and efficacy of fostrox (orally for 5 days in 21-day cycles), plus lenvatinib (standard doses), in locally advanced unresectable or metastatic HCC progressed on first-line/2L therapy (NCT03781934). A 3 + 3 dose-escalation design was used to determine the recommended phase II dose (RP2D). Results:Twenty-one patients were enrolled, and the median follow-up was 10.5 months. No dose-limiting toxicities were observed, and the RP2D of fostrox was established at 30 mg. All patients reported adverse events (AE), with 81% being grade ≥3 with possible relation to fostrox in 52.5% and to lenvatinib in 66.7% of cases. Fostrox-related AEs were mainly transient neutropenia and thrombocytopenia. Other AEs, mainly attributed to lenvatinib, were grade I/II and consistent with monotherapy use. Fostrox dose reduction and discontinuation rates were 29% and 5%, and for lenvatinib the rates were 52% and 14%, respectively. There were no signs of treatment-related liver function deterioration. The overall response rate was 24%, disease control rate was 81%, median time to progression was 10.9 months, median progression-free survival was 6.7 months, and median overall survival was 13.7 months. Fostrox PK analyses confirmed dose proportionality, and liver biopsies showed tumor-selective DNA damage. Conclusions:The combination of fostrox and lenvatinib demonstrated promising preliminary efficacy and tolerability after immunotherapy, supporting further investigation as a 2L option in advanced HCC.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
Purpose:Immunotherapy has significantly improved outcomes in advanced hepatocellular carcinoma (HCC). However, most patients eventually progress, and second-line (2L) options remain limited. Fostroxacitabine bralpamide (fostrox), a liver-targeted prodrug, was administered in combination with lenvatinib, aiming at enhancing antitumor activity while avoiding further deterioration of residual liver function. Patients and Methods:This multicenter, single-arm phase Ib/IIa study evaluated the safety, pharmacokinetics (PK)/pharmacodynamics, and efficacy of fostrox (orally for 5 days in 21-day cycles), plus lenvatinib (standard doses), in locally advanced unresectable or metastatic HCC progressed on first-line/2L therapy (NCT03781934). A 3 + 3 dose-escalation design was used to determine the recommended phase II dose (RP2D). Results:Twenty-one patients were enrolled, and the median follow-up was 10.5 months. No dose-limiting toxicities were observed, and the RP2D of fostrox was established at 30 mg. All patients reported adverse events (AE), with 81% being grade ≥3 with possible relation to fostrox in 52.5% and to lenvatinib in 66.7% of cases. Fostrox-related AEs were mainly transient neutropenia and thrombocytopenia. Other AEs, mainly attributed to lenvatinib, were grade I/II and consistent with monotherapy use. Fostrox dose reduction and discontinuation rates were 29% and 5%, and for lenvatinib the rates were 52% and 14%, respectively. There were no signs of treatment-related liver function deterioration. The overall response rate was 24%, disease control rate was 81%, median time to progression was 10.9 months, median progression-free survival was 6.7 months, and median overall survival was 13.7 months. Fostrox PK analyses confirmed dose proportionality, and liver biopsies showed tumor-selective DNA damage. Conclusions:The combination of fostrox and lenvatinib demonstrated promising preliminary efficacy and tolerability after immunotherapy, supporting further investigation as a 2L option in advanced HCC.
- Open Access
- 23 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (17) , OF1-OF10
A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
Purpose: Immunotherapy has significantly improved outcomes in advanced hepatocellular carcinoma (HCC). However, most patients eventually progress, and second-line (2L) options remain limited. Fostroxacitabine bralpamide (fostrox), a liver-targeted prodrug, was administered in combination with lenvatinib, aiming at enhancing antitumor activity while avoiding further deterioration of residual liver function. Patients and Methods: This multicenter, single-arm phase Ib/IIa study evaluated the safety, pharmacokinetics (PK)/pharmacodynamics, and efficacy of fostrox (orally for 5 days in 21-day cycles), plus lenvatinib (standard doses), in locally advanced unresectable or metastatic HCC progressed on first-line/2L therapy (NCT03781934). A 3 + 3 dose-escalation design was used to determine the recommended phase II dose (RP2D). Results: Twenty-one patients were enrolled, and the median follow-up was 10.5 months. No dose-limiting toxicities were observed, and the RP2D of fostrox was established at 30 mg. All patients reported adverse events (AE), with 81% being grade ≥3 with possible relation to fostrox in 52.5% and to lenvatinib in 66.7% of cases. Fostrox-related AEs were mainly transient neutropenia and thrombocytopenia. Other AEs, mainly attributed to lenvatinib, were grade I/II and consistent with monotherapy use. Fostrox dose reduction and discontinuation rates were 29% and 5%, and for lenvatinib the rates were 52% and 14%, respectively. There were no signs of treatment-related liver function deterioration. The overall response rate was 24%, disease control rate was 81%, median time to progression was 10.9 months, median progression-free survival was 6.7 months, and median overall survival was 13.7 months. Fostrox PK analyses confirmed dose proportionality, and liver biopsies showed tumor-selective DNA damage. Conclusions: The combination of fostrox and lenvatinib demonstrated promising preliminary efficacy and tolerability after immunotherapy, supporting further investigation as a 2L option in advanced HCC.
- 23 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (17) , OF1-OF10
Open AccessA Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
Purpose: Immunotherapy has significantly improved outcomes in advanced hepatocellular carcinoma (HCC). However, most patients eventually progress, and second-line (2L) options remain limited. Fostroxacitabine bralpamide (fostrox), a liver-targeted prodrug, was administered in combination with lenvatinib, aiming at enhancing antitumor activity while avoiding further deterioration of residual liver function. Patients and Methods: This multicenter, single-arm phase Ib/IIa study evaluated the safety, pharmacokinetics (PK)/pharmacodynamics, and efficacy of fostrox (orally for 5 days in 21-day cycles), plus lenvatinib (standard doses), in locally advanced unresectable or metastatic HCC progressed on first-line/2L therapy (NCT03781934). A 3 + 3 dose-escalation design was used to determine the recommended phase II dose (RP2D). Results: Twenty-one patients were enrolled, and the median follow-up was 10.5 months. No dose-limiting toxicities were observed, and the RP2D of fostrox was established at 30 mg. All patients reported adverse events (AE), with 81% being grade ≥3 with possible relation to fostrox in 52.5% and to lenvatinib in 66.7% of cases. Fostrox-related AEs were mainly transient neutropenia and thrombocytopenia. Other AEs, mainly attributed to lenvatinib, were grade I/II and consistent with monotherapy use. Fostrox dose reduction and discontinuation rates were 29% and 5%, and for lenvatinib the rates were 52% and 14%, respectively. There were no signs of treatment-related liver function deterioration. The overall response rate was 24%, disease control rate was 81%, median time to progression was 10.9 months, median progression-free survival was 6.7 months, and median overall survival was 13.7 months. Fostrox PK analyses confirmed dose proportionality, and liver biopsies showed tumor-selective DNA damage. Conclusions: The combination of fostrox and lenvatinib demonstrated promising preliminary efficacy and tolerability after immunotherapy, supporting further investigation as a 2L option in advanced HCC.
- Open Access
- 5 March 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (5) , 1595-1609
SEOM–GEMCAD–TTD clinical guideline for the diagnosis and treatment of esophageal cancer (update 2025)
Esophageal cancer represents an aggressive disease positioned as the seventh-leading cause of death from cancer. Esophageal cancer comprises two different diseases that should be distinguished by histology, i.e., squamous cell carcinoma and adenocarcinoma. The epidemiology and molecular differences between these two entities explain their different responsiveness to novel treatments which should be treated independently. The improvement in outcomes of patients with esophageal cancer are obtained when a multidisciplinary therapeutic strategy is utilized. The introduction of targeted therapies including immunotherapy has markedly improved patient outcomes. We present an updated version of the Spanish esophageal cancer guidelines, summarizing the current evidence and available therapies for the treatment of esophageal cancer.
- 5 March 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (5) , 1595-1609
Open AccessSEOM–GEMCAD–TTD clinical guideline for the diagnosis and treatment of esophageal cancer (update 2025)
Esophageal cancer represents an aggressive disease positioned as the seventh-leading cause of death from cancer. Esophageal cancer comprises two different diseases that should be distinguished by histology, i.e., squamous cell carcinoma and adenocarcinoma. The epidemiology and molecular differences between these two entities explain their different responsiveness to novel treatments which should be treated independently. The improvement in outcomes of patients with esophageal cancer are obtained when a multidisciplinary therapeutic strategy is utilized. The introduction of targeted therapies including immunotherapy has markedly improved patient outcomes. We present an updated version of the Spanish esophageal cancer guidelines, summarizing the current evidence and available therapies for the treatment of esophageal cancer.
- Open Access
- 28 June 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (9) , 3833-3835
Correction: Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)
- 28 June 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (9) , 3833-3835
Open AccessCorrection: Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)
- Open Access
- 12 March 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (9) , 3580-3594
Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)
Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA. Four key biomarkers are essential for targeted therapy: HER2 overexpression/amplification, deficient mismatch repair/microsatellite instability (dMMR/MSI), PD-L1, and Claudin18.2 expression. Immunohistochemistry is the recommended method for these biomarkers evaluation. In addition, the assessment of biomarkers like FGFR2b is likely to become routine in the near future. Experts from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have formed a consensus to optimize biomarker detection and usage in clinical practice. Their recommendations aim to improve personalized treatment strategies for GEA and ESCC patients, integrating new diagnostic insights into routine care.
- 12 March 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (9) , 3580-3594
Open AccessBiomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)
Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA. Four key biomarkers are essential for targeted therapy: HER2 overexpression/amplification, deficient mismatch repair/microsatellite instability (dMMR/MSI), PD-L1, and Claudin18.2 expression. Immunohistochemistry is the recommended method for these biomarkers evaluation. In addition, the assessment of biomarkers like FGFR2b is likely to become routine in the near future. Experts from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have formed a consensus to optimize biomarker detection and usage in clinical practice. Their recommendations aim to improve personalized treatment strategies for GEA and ESCC patients, integrating new diagnostic insights into routine care.
- Open Access
- 9 January 2025
- Published by Universidad Complutense de Madrid (UCM) in Arte, Individuo y Sociedad
- Vol. 37 (1) , 159-179
Aplicación de las terapias creativas en el estudio de los efectos emocionales y psicológicos sobre pacientes oncológicos adultos en el Hospital Universitario Doce de Octubre
Este estudio cuasi-experimental con grupo control y metodología mixta evalúa los efectos de un programa de arteterapia y musicoterapia en pacientes adultos oncológicos hospitalizados. Tras tres sesiones de intervención, el grupo experimental experimentó mejoras significativas en dolor, ansiedad, depresión y distrés emocional en comparación con el grupo control, que recibió tratamiento médico estándar. Las reducciones significativas incluyeron el dolor (-4.72; p < 0.001), la ansiedad (-4.78; p < 0.001), la depresión (-4.06; p < 0.001) y el distrés (-5.28; p < 0.001), medidas a través de las escalas EVA, HADS, PHQ-9, y DME/TD. Además, se observaron mejoras fisiológicas notables, como la reducción de la presión arterial sistólica (-25.34 mmHg) y diastólica (-11.92 mmHg), así como de la frecuencia cardíaca. Aunque los cambios en la autonomía funcional evaluada con el índice BABVD no alcanzaron significancia estadística, se observó una tendencia positiva. Las entrevistas semiestructuradas revelaron mejoras en el bienestar emocional, la motivación y las relaciones interpersonales. Estos hallazgos subrayan el valor de integrar terapias creativas como complemento en la atención oncológica, contribuyendo a mejorar el bienestar físico y emocional de los pacientes hospitalizados.
- 9 January 2025
- Published by Universidad Complutense de Madrid (UCM) in Arte, Individuo y Sociedad
- Vol. 37 (1) , 159-179
Open AccessAplicación de las terapias creativas en el estudio de los efectos emocionales y psicológicos sobre pacientes oncológicos adultos en el Hospital Universitario Doce de Octubre
Este estudio cuasi-experimental con grupo control y metodología mixta evalúa los efectos de un programa de arteterapia y musicoterapia en pacientes adultos oncológicos hospitalizados. Tras tres sesiones de intervención, el grupo experimental experimentó mejoras significativas en dolor, ansiedad, depresión y distrés emocional en comparación con el grupo control, que recibió tratamiento médico estándar. Las reducciones significativas incluyeron el dolor (-4.72; p < 0.001), la ansiedad (-4.78; p < 0.001), la depresión (-4.06; p < 0.001) y el distrés (-5.28; p < 0.001), medidas a través de las escalas EVA, HADS, PHQ-9, y DME/TD. Además, se observaron mejoras fisiológicas notables, como la reducción de la presión arterial sistólica (-25.34 mmHg) y diastólica (-11.92 mmHg), así como de la frecuencia cardíaca. Aunque los cambios en la autonomía funcional evaluada con el índice BABVD no alcanzaron significancia estadística, se observó una tendencia positiva. Las entrevistas semiestructuradas revelaron mejoras en el bienestar emocional, la motivación y las relaciones interpersonales. Estos hallazgos subrayan el valor de integrar terapias creativas como complemento en la atención oncológica, contribuyendo a mejorar el bienestar físico y emocional de los pacientes hospitalizados.
- Open Access
- 24 June 2024
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (11) , 2800-2811
SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)
Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A.
- 24 June 2024
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (11) , 2800-2811
Open AccessSEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)
Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A.